Key result
Atorvastatin 80 mg cuts plaque inflammation ~11% more than 10 mg at 12 weeks.
Why the study?
Does atorvastatin 80 mg reduce atherosclerotic plaque inflammation compared to atorvastatin 10 mg in adults with risk factors or established atherosclerosis?
RCT (n=83)
double-blind
randomized
Yes
Does atorvastatin 80 mg reduce atherosclerotic plaque inflammation compared to atorvastatin 10 mg in adults with risk factors or established atherosclerosis?
High-dose atorvastatin rapidly reduces atherosclerotic plaque inflammation compared to low-dose atorvastatin, independent of lipid profile changes.
OBJECTIVES: The study sought to test whether high-dose statin treatment would result in greater reductions in plaque inflammation than low-dose statins, using fluorodeoxyglucose-positron emission tomography/computed tomographic imaging (FDG-PET/CT). BACKGROUND: Intensification of statin therapy reduces major cardiovascular events. METHODS: Adults with risk factors or with established atherosclerosis, who were not taking high-dose statins (n = 83), were randomized to atorvastatin 10 versus 80 mg in a double-blind, multicenter trial. FDG-PET/CT imaging of the ascending thoracic aorta and carotid arteries was performed at baseline, 4, and 12 weeks after randomization and target-to-background ratio (TBR) of FDG uptake within the artery wall was assessed while blinded to time points and treatment. RESULTS: Sixty-seven subjects completed the study, providing imaging data for analysis. At 12 weeks, inflammation (TBR) in the index vessel was significantly reduced from baseline with atorvastatin 80 mg (% reduction [95% confidence interval]: 14.42% [8.7% to 19.8%]; p < 0.001), but not atorvastatin 10 mg (% reduction: 4.2% [-2.3% to 10.4%]; p > 0.1). Atorvastatin 80 mg resulted in significant additional relative reductions in TBR versus atorvastatin 10 mg (10.6% [2.2% to 18.3%]; p = 0.01) at week 12. Reductions from baseline in TBR were seen as early as 4 weeks after randomization with atorvastatin 10 mg (6.4% reduction, p < 0.05) and 80 mg (12.5% reduction, p < 0.001). Changes in TBR did not correlate with lipid profile changes. CONCLUSIONS: Statin therapy produced significant rapid dose-dependent reductions in FDG uptake that may represent changes in atherosclerotic plaque inflammation. FDG-PET imaging may be useful in detecting early treatment effects in patients at risk or with established atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Tawakol et al. (2013) conducted an RCT in Atherosclerosis or risk factors (n=83). Atorvastatin vs. Atorvastatin 10 mg was evaluated on Reduction in target-to-background ratio (TBR) of FDG uptake within the artery wall at 12 weeks (10.6% additional relative reduction, 95% CI 2.2% to 18.3%, p=0.01). Atorvastatin 80 mg produced a significantly greater reduction in atherosclerotic plaque inflammation compared to atorvastatin 10 mg at 12 weeks (10.6% additional relative reduction; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: